The majority of heterocycle compounds and typically common heterocycle fragments
present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility …

The field of chronic lymphocytic leukemia (CLL) has witnessed considerable change since
the time clinical staging was introduced in clinical practice in 1975. Over the years, the …

In recent years, the number of approved and investigational agents that can be safely
administered for the treatment of lymphoma patients for a prolonged period of time has …

The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-
kinase-δ inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic …

Heterocyclic scaffolds are widely utilized for drug design by taking into account the
molecular structure of therapeutic targets that are related to a broad spectrum of ailments …

Simple Summary The development of small agents targeting the B-cell receptor (BCR)
pathway revolutionized the treatment of chronic lymphocytic leukemia (CLL). BCR …

Chronic lymphocytic leukemia (CLL) is caused by the accumulation of malignant B cells due
to a defect in apoptosis and the presence of small population of proliferating cells principally …

Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the western
world. Despite the positive clinical effects of new targeted therapies, CLL still remains an …

Patients with chronic lymphocytic leukemia can be divided into three categories: those who
are minimally affected by the problem, often never requiring therapy; those that initially …

B cell receptor (BCR) signaling is a central pathway promoting the survival and proliferation
of normal and malignant B cells. Chronic lymphocytic leukemia (CLL) arises from mature B …